GSK Poaches New Vaccines R&D Chief From Pfizer
Looking To Close Gap On mRNA Leaders
Executive Summary
Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.
You may also be interested in...
GSK/Medicago COVID-19 Vaccine Looks Like Also-Ran But Antibody Shows Value Against Omicron
GSK looks unlikely to be a major player in COVID-19 vaccines, even in boosters, but its partnership with Vir could pay off handsomely.
Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.
GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.